All Updates

All Updates

icon
Filter
Product updates
Guardant Health launches enhanced Guardant360 TissueNext test with up to 500 biomarkers for cancer detection
Precision Medicine
Jun 4, 2024
This week:
Geographic expansion
Partnerships
Lemonade partners with Homesite to expand home insurance services
InsurTech: Personal Lines
Jun 14, 2024
Funding
BayaniPay raises USD 3 million in seed funding to expand payment solutions
Neobanks
Jun 14, 2024
Partnerships
Carbonfuture and Swiss Re partner for long-term carbon removal through biochar
Carbon Management Software
Jun 13, 2024
Funding
Sidekick raises GBP 8.5 million in seed and debt funding to support expansion
Retail Trading Infrastructure
Jun 13, 2024
Partnerships
Climatiq and Epicor partner to reduce CO2 emissions in supply chains
Carbon Management Software
Jun 13, 2024
Product updates
EHang's pilotless eVTOL aircraft concludes first flight launch in Saudi Arabia
Passenger eVTOL Aircraft
Jun 13, 2024
Partnerships
Skyports partners with Unified Aviation to accelerate global network release
Passenger eVTOL Aircraft
Jun 13, 2024
Industry news
Partnerships
USSF chooses Blue Origin, SpaceX, and ULA for ~USD 5.6 billion Pentagon launch contracts
Space Travel and Exploration Tech
Jun 13, 2024
Funding
AnyCreek raises USD 1.8 million in seed funding to enhance platform and expand into new markets
Travel Tech
Jun 13, 2024
Funding
Zeta Labs raises USD 2.9 million in pre-seed funding to develop autonomous AI agent
Generative AI Applications
Jun 13, 2024
Precision Medicine

Precision Medicine

Jun 4, 2024

Guardant Health launches enhanced Guardant360 TissueNext test with up to 500 biomarkers for cancer detection

Product updates

  • Guardant Health has introduced a new version of its Guardant360 TissueNext test, identifying 498 genes in tumor tissue samples. The test will be offered to Medicare fee-for-service patients with advanced solid tumor cancers.

  • Key features of the product include expanded gene coverage of close to 500 biomarkers, compatibility with Guardant’s other genomic profiling tests, and operational workflow improvements for quicker results. 

  • The company claims that the test can help oncologists make more informed decisions about treatment strategies and potentially boost patient outcomes by identifying a broader range of actionable biomarkers in tumor tissue.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.